• Chen Su, Hao Wu, Xiaoyu Yang, Bing Zhao, and Renliang Zhao.
• Neurology Department, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China.
• Medicine (Baltimore). 2021 Jul 30; 100 (30): e26749e26749.

BackgroundCerebral small vessel disease is relevant to hypertension. We tried to figure out whether antihypertensive treatment is beneficial for this disease.MethodsWe systematically searched PubMed, Embase, and Cochrane electronic databases for randomized controlled trials about white matter hyperintensities (WMH), brain atrophy, microbleeds, and lacunar infarcts with antihypertensive treatment and performed a meta-analysis.ResultsWe identified 7 trials on white matter hyperintensities and brain atrophy with antihypertensive treatment. Pooled analysis showed antihypertensive treatment performed positively in the progression of WMH (standardized mean difference, -0.22; 95% CI, -0.36 to -0.07, I^2 = 52%). And in the subgroup meta-analysis, only lower SBP controlled level (110-129 mm Hg) had effect on the progression of WMH (standardized mean difference, -0.37; 95% CI, -0.54 to -0.29, I^2 =0). The meta-regression showed larger difference of SBP in treatment groups having a smaller WMH progression. Antihypertensive treatment is not significant in the progression of brain atrophy (standardized mean difference, -0.02; 95% CI, -0.26 to 0.30, I^2 = 85%). Only 1 trial reported the new patients of lacunar infarcts in the follow-up, no association with antihypertensive treatment (odds ratio, 2.2; 95% CI, 0.4-12.1; P = .36).ConclusionsAntihypertensive treatment is beneficial for cerebral small vessel disease on white matter hyperintensities progression, but no impact on brain atrophy. And lower SBP level is more effective on the progression of WMH. There is not enough evidence to prove the relationship between antihypertensive treatment and lacunar stroke, microbleeds.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

8 keywords...

hide…